The company said epetraborole is the first drug candidate with statistically favorable patient reported outcome-based improvement in a treatment-refractory Mycobacterium avium Complex population. AN2 ...

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on INSM stock, giving a Buy rating on November 5. Graig ...

Assetmark Inc. raised its holdings in Insmed Incorporated (NASDAQ:INSM – Free Report) by 12.9% in the 3rd quarter, according ...

A fourth of patients with Mycobacterium avium complex pulmonary disease (MAC-PD) whose pre- and on-treatment isolates were the same species had genetically distinct strains within the same species in ...

Expert Rev Anti Infect Ther. 2011;9(9):787-802.